Paratek Pharmaceuticals to Present at the Jefferies 2022 Healthcare Conference
Paratek Pharmaceuticals (Nasdaq: PRTK) announced that CEO Evan Loh will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, from 3:30 to 3:55 p.m. ET in New York City. The session will be available for on-demand viewing starting June 9 on their website. Paratek specializes in developing novel therapies for life-threatening diseases and is known for its lead product, NUZYRA, an antibiotic used to treat bacterial pneumonia and skin infections. The company also explores treatments for rare diseases, with potential market opportunities exceeding $1 billion.
- None.
- None.
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Evan Loh, M.D., chief executive officer, will participate in a fireside chat June 9 from 3:30 to 3:55 p.m. Eastern Time at the Jefferies Healthcare Conference in New York City.
Dr. Loh’s event will be available to view on-demand at: https://wsw.com/webcast/jeff240/prtk/1871025 and under “Presentations & Events" in the Investors section of the company's website at https://www.paratekpharma.com/investor-relations beginning June 9 at 3:30 p.m. and for the next 90 days.
Members of Paratek’s senior management team also will be available for one-on-one investor meetings June 9.
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
The company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. Paratek estimates this opportunity represents a potential
Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world.
In 2019, Paratek was awarded a contract from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA), now valued at up to
Forward Looking Statements
This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2021 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.
CONTACT:
For Investors:
Hans Vitzthum
LifeSci Advisors
ir@ParatekPharma.com
Phone: 617-430-7578
For Media:
Christine Fanelle
Scient PR
Christine@scientpr.com
Phone: 215-595-5211
FAQ
When is the Paratek Pharmaceuticals fireside chat scheduled?
Where can I watch the Paratek Pharmaceuticals fireside chat?
What is Paratek Pharmaceuticals' lead commercial product?
What market opportunities is Paratek Pharmaceuticals pursuing?
What is the stock symbol for Paratek Pharmaceuticals?
